Rachel Williams


Rachel Williams
Rachel Williams is an associate in Weil’s Antitrust practice. She focuses on civil antitrust, class action, and other complex litigation, as well as transactional regulatory clearance, antitrust counseling, and government investigations.

Rachel also has an active pro bono practice, which of late has included work on behalf of the Innocence Project and Legal Services of New York.

Rachel received her B.S. in Business Administration and her M.S. in Finance from University of Florida. She earned her J.D. from University of Florida Fredric G. Levin College of Law. During law school, she served as a legal intern in the Enforcement Division at the Securities and Exchange Commission.

Rachel’s recent experience includes serving on Weil teams representing:

  • Saks Fifth Avenue in successfully securing a motion to dismiss without prejudice for Saks Fifth Avenue and co-defendant luxury retail brands in an alleged “no poach” antitrust class action in which Plaintiffs claimed Saks orchestrated “no hire” agreements with each luxury brand.
  • Grubhub in a purported antitrust class action brought against Grubhub and other meal delivery services alleging that defendants use their dominant market positions to force restaurants to charge elevated prices to all of their customers through the use of certain contract restrictions between defendants and the restaurants that utilize their platforms.
  • Meta Platforms (f/k/a Facebook) in its acquisition of Within, the immersive media startup behind the VR fitness service Supernatural.
  • Meta Platforms (f/k/a Facebook) in its $1 billion acquisition of Kustomer, a customer relationship management (CRM) company.
  • MGM Resorts International in its $1.63 billion acquisition of The Cosmopolitan of Las Vegas from Blackstone.
  • Magellan Health in the $850 million sale of its Magellan Complete Care business to Molina Healthcare, Inc.
  • Regeneron Pharmaceuticals in connection with monopolization and other claims against Novartis relating to actions taken to prevent competition from Regeneron’s PFS version of Eylea.
  • Allergan in a successful defense against antitrust counterclaims brought by Akorn related to the eyelash hair-growth drug product LATISSE®, including the allegation that this case and prior patent infringement lawsuits were “sham” litigations aimed a harming Akorn, and that these cases hurt competition in the broader market for generic competition with LATISSE®. Weil and patent co-counsel filed a motion to dismiss Akorn’s patent and antitrust counterclaims and to strike their related affirmative defenses on the basis that Allergan’s current and prior lawsuits were not “shams.” The Court granted Allergan’s motion to dismiss and also struck three of Akorn’s related affirmative defenses, ultimately concluding that all of Allergan’s prior litigations had objective merit and thus did not violate U.S. antitrust law.
  • Rent the Runway (RTR) against allegations by FashionPass that RTR’s contracts with fashion designers allegedly harmed competition and tortiously interfered with business opportunities. After obtaining a dismissal of the initial complaint, the matter was successfully resolved.
  • A global chemicals manufacturer in connection with a Department of Justice criminal antitrust investigation regarding alleged price fixing in the market for liquid aluminum sulfate, a key water treatment chemical, as well as in related class action litigation and state false claims act cases.
  • A major e-commerce company in a contract dispute relating to a multi-year operating agreement with a former business partner. Following a five-day evidentiary trial and post-trial briefing, Weil secured a complete victory and significant damages for the client.

Firm News & Announcements, Latest Thinking

Firm News & Announcements

Latest Thinking

View all